ANZUP Cancer Trials Group Ltd is the peak urogenital and prostate cancer cooperative trials group in the region. The organisational structure of ANZUP reflects its corporate governance and operational areas of responsibility.
The Board comprises the Directors of the Company and is responsible for financial management and corporate governance of the Company. Its roles are to set the strategic direction, to appoint its CEO and to provide guidance and oversight to the management of the Company and its governance. The Board consists of five elected Directors and four Appointed Directors. The Board meets approximately every two months and where possible one face-to-face meeting annually.
The Governance Committee is appointed by the Board to assist it to fulfil its responsibilities and to ensure that the Board fulfils its legal, ethical, and functional responsibilities through adequate governance policy development, recruitment strategies, monitoring of Board activities, and evaluation of Board members’ performance.
FINANCE AND AUDIT COMMITTEE
The Finance and Audit Committee (‘FAC’) assists the Board in fulfilling its responsibilities, such that:
- it oversees the financial reporting process to ensure full disclosure of the Company’s financial information;
- it ensures that the internal financial management of the Company has adequate accounting processes and systems, including assessing the performance of the external auditor;
- it ensures that it receives from management reliable and timely financial reporting.
FUNDRAISING AND PARTNERSHIPS SUBCOMMITTEE
The Fundraising and Partnerships Subcommittee reports to the FAC. Its main objectives is to identify and pursue opportunities to raise awareness and additional revenue to support ANZUP to achieve its mission.
BOARD AND MANAGEMENT
The Board has delegated the day-to-day management of the Company to the CEO in accordance with the processes that the Board approves, namely:
- financial and capital management and reporting;
- information technology including cyber security protocols; and
- compliance with the limitations attached to government grants for research and aligned to the purpose and objectives of the company.
The Board has in place procedures to assess the performance of the CEO and to appoint and replace the CEO, if and when necessary.
CONSUMER ADVISORY PANEL (CAP)
The ANZUP CAP reports to the Board. It comprises consumer/community representatives who contribute at all levels of governance, from the Board and SAC and its subcommittees through to specific trials and research projects. The CAP also provides a conduit for communication from ANZUP back to the community in order to promote clinical trial research. The CAP meets quarterly and where possible face-to-face at least once per year.
SCIENTIFIC ADVISORY COMMITTEE (SAC)
The Scientific Advisory Committee (‘SAC’) is advised by disease specific subcommittees (Prostate, Renal, Germ Cell and Bladder urothelial and penile) and non-disease-specific subcommittees (Quality of Life & Supportive Care, Translational Research and Consumer Advisory Panel). The SAC and the SAC subcommittees are responsible for oversight of clinical trial research to improve the treatment of bladder, kidney, testicular, penile and prostate cancers.
The SAC consists of a core of members representing the major disciplines relevant to ANZUP, nominated and appointed upon the recommendation of those groups. In addition, Chairs of the SAC subcommittees are members of the SAC by virtue of their appointment as Chair. The SAC members are appointed by the Board. The SAC meets quarterly and where possible one annual face-to-face meeting during the ASM.
The SAC is advised by disease specific subcommittees (Prostate, Renal, Germ Cell and Bladder/Urothelial/Penile) and non-disease-specific subcommittees (Quality of Life & Supportive Care and Translational Research). The disease specific subcommittees are responsible for oversight of trials within their portfolios, as well as development of new trial concepts. These subcommittees meet quarterly virtually and at least once face-to-face per year. The non-disease-specific subcommittees are involved as required in trial development and management in order to ensure maximum value is added to every trial. These subcommittees meet quarterly and where possible at least once face to-face per year.
OPERATIONS EXECUTIVE COMMITTEE
This committee consists of representatives from ANZUP and each of its coordinating centres – the NHMRC Clinical Trials Centre at The University of Sydney and the Centre for Biostatistics and Clinical Trials. The committee is responsible for oversight of trials and group operations. This committee meets approximately once per month or most often if required.
INDEPENDENT DATA AND SAFETY MONITORING COMMITTEE (IDSMC)
The broad aim of the IDSMC is to evaluate the plausible benefits and risks associated with patient participation in ANZUP trials. The IDSMC comprises at least three members who are experienced in clinical research and are not conflicted with ANZUP. The committee oversees ANZUP studies and co-opts others onto it when additional advice is required. The IDSMC advises the relevant Trial Management Committee (TMC) Chair(s), ANZUP Group Chair, CEO and Scientific Advisory Committee Chair.
TRIAL MANAGEMENT COMMITTEE (TMC)
Each trial has a TMC that meets approximately quarterly by teleconference to ensure oversight of the trial.